Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel + Gemcitabine for Pediatric Relapsed/Refractory Solid Tumors
NCT03507491Phase 1Completed
- Sponsor
- Emory University
- Start
- Aug 2018
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel in solid tumor, sponsored by Emory University. Primary endpoints: Maximum Tolerated Dose at Day 28 and Toxicity of nab-paclitaxel up to 96 weeks. Started Aug 2018; status: completed.
02
Drugs
paclitaxel
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03507491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03507491.